Inhibikase Therapeutics Inc (NASDAQ: IKT) — Perfil da empresa, notícias e dados financeiros
Inhibikase Therapeutics develops therapies for neurodegenerative diseases, focusing on Parkinson's disease treatment approaches.
Inhibikase Therapeutics Inc
Inhibikase Therapeutics (NASDAQ:IKT) is a clinical-stage pharmaceutical company focused on developing therapies for neurodegenerative diseases, notably Parkinson's disease and related disorders. By targeting the underlying pathologies that contribute to these conditions, Inhibikase aims to halt or slow their progression. The company's pipeline includes projects that explore innovative treatment approaches, leveraging kinase inhibition strategies to potentially safeguard neuronal function and improve outcomes for patients facing these challenging diseases. Their objective is to transform the therapeutic landscape for neurodegenerative disorders through science-driven innovation, offering hope to patients and families affected by these debilitating conditions.
Resumo
Operações
Produtos e/ou serviços de Inhibikase Therapeutics Inc
- IkT-148009, a c-Abl tyrosine kinase inhibitor aimed at treating Parkinson's disease and related disorders.
- IkT-001Pro, a formulation enhancement of imatinib for improved brain penetration and efficacy against neurodegenerative diseases.
- Abelson Tyrosine Kinase (c-Abl) Inhibition Platform, targeting the underlying pathology of neurodegenerative conditions by inhibiting c-Abl.
- RAMP™ technology, a proprietary drug delivery platform designed to enhance the delivery of therapeutics across the blood-brain barrier.
- IkT-01427, a second-generation c-Abl tyrosine kinase inhibitor for broader neurodegenerative disease applications.
- Pipeline of kinase inhibitors in various stages of preclinical development targeting diseases with high unmet medical needs.
equipe executiva do Inhibikase Therapeutics Inc
- Mark T. IwickiCEO & Director
- Christopher H. CabellPresident, Head of Research & Development and Chief Medical Officer
- David John McIntyreChief Financial Officer
- John AdamsChief Scientific Officer
- Jeffrey J. KagyChief Human Resources Officer
- Chadwick J. OrevilloExecutive VP & Head of Development Operations
- Timothy J. PigotChief Commercial & Strategy Officer
Principais indicadores financeiros
Resultados divulgados pela Inhibikase Therapeutics Inc, em USD.
- Cap. de mercado
- 226 mi
- Receita (TTM)
- 1
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -52 mi | -48,3 mi | |
| 0 | -28,6 mi | -27,5 mi | |
| 260,5 mil | -20,1 mi | -19 mi | |
| 123,4 mil | -18,1 mi | -18,1 mi |